Sara Zarnegar-Lumley,Jennifer L McNeer
Sara Zarnegar-Lumley
Recent molecular studies have identified subgroups of acute lymphoblastic leukemia (ALL) driven by genomic aberrations rather than structural chromosome rearrangements or aneuploidy. Recent years have brought the advent of immunotherapy to ...
Elizabeth Sokol,Amy L Walz
Elizabeth Sokol
Neuroblastoma and Wilms tumor are common pediatric malignancies. For both tumors, management relies on risk stratification that is based on a combination of clinical and molecular factors. Neuroblastoma is risk-stratified based on age, stag...
Rayane El Rahi,Murat Yüce,Bachir Taouli
Rayane El Rahi
Primary liver cancer, encompassing hepatocellular carcinoma and cholangiocarcinoma, represents a growing global health burden with significant morbidity and mortality. Imaging is central to the clinical management of these malignancies, inf...
Thomas E Clancy
Thomas E Clancy
Kishan Patel,Alison Moskowitz
Kishan Patel
Combined modality therapy (cytotoxic chemotherapy followed by consolidative radiation [RT]) has historically been the standard-of-care for patients with early-stage Hodgkin lymphoma (HL). However, novel agents, such as brentuximab vedotin (...
Carrie Sha,Sarah C Rutherford
Carrie Sha
Outcomes for older patients with classic Hodgkin lymphoma (cHL) are improving with the inclusion of novel agents into frontline therapy. The sequential brentuximab vedotin (BV) and doxorubicin, vinblastine, dacarbazine (AVD) regimen was sta...
Alexandra D Dreyfuss,Joachim Yahalom
Alexandra D Dreyfuss
Radiation therapy (RT) has played a central role in the management of classic Hodgkin lymphoma (cHL) for over a century and remains an integral component of modern, risk-adapted treatment strategies. Advances in systemic therapy, molecular ...
Daniel Klein Reef,Natalie Sophia Grover
Daniel Klein Reef
The CD30 antibody-drug conjugate, brentuximab vedotin, and PD-1 inhibitors, nivolumab and pembrolizumab have transformed the care of patients with Hodgkin lymphoma and have been incorporated into earlier lines of therapy. However, there are...
New Tools and Drugs Improve the Balance Between Cure and Toxicity in Hodgkin Lymphoma [0.03%]
新的工具和药物改善了霍奇金淋巴瘤治疗的疗效和毒副反应之间的平衡
Alex F Herrera,Alison J Moskowitz
Alex F Herrera
New Developments in Hodgkin's Lymphoma: Outcomes and Disparities in Classic Hodgkin Lymphoma [0.03%]
经典霍奇金淋巴瘤的疗效及差异性研究新进展
Katia M Crisler,Mallorie B Heneghan,Justine M Kahn
Katia M Crisler
Despite continued advances, survival among patients with Hodgkin lymphoma differs by age, race and ethnicity, socioeconomic status, insurance, and treatment location. Inequities are evident across the cancer care continuum, from timely diag...